Name: Rare Tumours of the Kidney
SKU: 1-0364-4317-5
Availability: InStock

Rare Tumours of the Kidney

Review and Update

By: Anthony Kodzo-Grey Venyo

£94.99

Rare malignant neoplasms of the kidney have aggressive outcomes but are not covered in most books of Urology, Surgery, and Medicine. This book focuses on these rare neoplasms, providing updated information on a heterogeneous group of disorders with distinct abnormalities.

In 2023, an estimated 81,800 adults including 52,360 men and 20,440 women within the “United states of America” (USA) were diagnosed with cancer of the…

In 2023, an estimated 81,800 adults including 52,360 men and 20,440 women within the “United states of America” (USA) were diagnosed with cancer of the kidney. Globally, an estimated 431,288 individuals were diagnosed with kidney cancer. There have been about 13,300 new kidney cancer cases within the United Kingdom every year, which means on average 36 kidney cancer cases as per 2016 to 2018 data. RCC may be sporadic (-96%) or familial (4%) and belongs to a heterogeneous group of disorders that are subclassified into several distinct sub-types associated with distinct genetic abnormalities. Rare malignant neoplasms of the kidney portend aggressive biological features and outcomes but had not been covered in most books of Urology, Surgery and Medicine. The ensuing book has focused on rare neoplasms of the kidney to provide update information on neoplasms of the kidney.

Anthony Kodzo-Grey Venyo, MB CHB FRCSED, FRCSI, FGCS UROL, LLM, Educational Supervisor Certificate (Royal College of Physicians, London) and Accreditation, and Medical Examiner Member of the Royal College of Pathologists, London, is a recently, though temporarily, retired clinician and urologist, having spent many years undertaking clinical training and work experience in Ghana and the United Kingdom to forge a career in urology (Senior Clinical Fellow Urologist). He is currently writing different books on various urology topics. He is a member of the editorial board of a number of international journals. His interests cover a variety of rare afflictions and neoplasms of the urogenital system as well as various important diseases afflicting human beings. He has clinical and laboratory research experience. He has published many articles and some book chapters as well as a book. He is also currently a reviewer for some journals.

Hardback

ISBN: 1-0364-4317-5
ISBN13: 978-1-0364-4317-7
Date of Publication: 2025-03-24

Ebook

ISBN: 1-0364-4318-3
ISBN13: 978-1-0364-4318-4
Date of Publication: 2025-03-24

Category: Health Science, Medicine, Cancer

Pages: 707

Subject Codes:

BIC: MJCL
THEMA: MJCL

Pages: 707

Meet The Author

Anthony Kodzo-Grey Venyo

Additional Miscellaneous Rare Tumours of the Kidney

Review and Updates

By: Anthony Kodzo-Grey Venyo

£70.99

Rare kidney tumours are often misdiagnosed, leading to poor prognosis. As these tumours are not covered in most surgery and urology textbooks, this book details miscellaneous rare tumours of the kidney which all clinicians should know about to improve diagnosis and treatment.

Rare Afflictions of the Scrotum and Scrotal Contents

By: Anthony Kodzo-Grey Venyo

£70.99

Rare scrotal afflictions mimic common conditions, leading to misdiagnosis, delayed treatment, and patient distress. Since most medical books do not cover these lesions in detail, this book provides a vital reference for clinicians to ensure accurate and timely diagnosis.

Rare Tumours of the Prostate Gland

By: Anthony Kodzo-Grey Venyo

£70.99

Rare types of prostate cancer are aggressive, have poor prognoses, and are often misdiagnosed. This book updates the literature on these rare neoplasms to alert clinicians and encourage research to find more effective treatment options.

Miscellaneous Rare Tumours of the Prostate Gland

By: Anthony Kodzo-Grey Venyo

From £39.99

Rare prostate cancers have an aggressive biological behaviour and inferior prognosis, often due to delayed or incorrect diagnosis. This book updates the literature on rare neoplasms of the prostate to help speed up diagnosis and treatment and encourage research into new options.